Gene expression changes associated with chemically induced rat mammary carcinogenesis

Molecular Carcinogenesis

Volumn 20, Issue 2, 1997, Pages 204-215

  Lu, Junxuan ^a   Pei, Hongying ^a   Kaeck, Mark ^a   Thompson, Henry J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Cancer markers; Differential display; Gene expression; Mammary carcinogenesis; Molecular cloning

Indexed keywords

TUMOR MARKER;

ANIMAL CELL; ARTICLE; BREAST CARCINOGENESIS; CANCER PREVENTION; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; DNA DAMAGE; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENE MUTATION; GENE REARRANGEMENT; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; RAT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADENOCARCINOMA; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CARCINOGENS; CLONING, MOLECULAR; COLONIC NEOPLASMS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION; GENETIC MARKERS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; MICE; MOLECULAR SEQUENCE DATA; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SEQUENCE HOMOLOGY, AMINO ACID;

ANIMALIA; BOVINAE;

EID: 0030724701     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199710)20:2<204::AID-MC7>3.0.CO;2-M     Document Type: Article

References (61)

1. Gullino PM, Pettigrew HM, Grantham FH. N-Nitrosomethylurea as mammary gland carcinogen in rats. J Natl Cancer Inst 54:401-414, 1975.
2. McCormick DL, Adamowski CB, Fiks A, Moon RC. Lifetime dose-response relationship for mammary tumor induction by a single administration of N-methyl-N-nitrosourea. Cancer Res 41:1690-1694, 1981.
3. Welch CW. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: A review and tribute to Charles Brenton Muggins. Cancer Res 45:3415-3443, 1985.
4. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, vanZwieten MJ. Biology of disease: Comparative study of human and rat mammary tumorigenesis. Lab Invest 62:244-278, 1990.
5. Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer (1). N Engl J Med 327:319-328, 1992.
6. Weinberg RA. The integration of molecular genetics into cancer management. Cancer 70:1653-1658, 1992.
7. van de Vijver MJ. Molecular genetic changes in human breast cancer. Adv Cancer Res 61:25-56, 1993.
8. Conti CJ. Mutations of genes of the ras family in human and experimental tumors. Prog Clin Biol Res 376:357-378, 1992.
9. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71, 1994.
10. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266:120-122, 1994.
11. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792, 1995.
12. Sukumar S, Notario V, Martin-Zanca D, Barbacaid M. Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature 306:658-661, 1983.
13. Zarbl H, Sukumar S, Arthur AV, Martin-Zanca D, Barcacid M. Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature 315:382-385, 1985.
14. Zarbl H, Sukumar S, Arthur AL, Martin-Zanca D, Barbacid M. Activation of H-ras-1 oncogenes by chemical carcinogens. Basic Life Sci 38:385-397, 1986.
15. Zhang R, Haag JD, Gould MN. Reduction in the frequency of activated ras oncogenes in rat mammary carcinomas with increasing N-methyl-N-nitrosourea doses or increasing prolactin levels. Cancer Res 50:4286-4290, 1990.
16. Slamon DJ, Clark GM, Wong SG, et al Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987.
17. Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA. Alteration to either c-erbB(neu) or c-myc protooncogenes in breast carcinomas correlate with short-term prognosis. Oncogene 1:423-430, 1987.
18. Zhou D, Battifora H, Yokota J, Yamamoto T, Clive MJ. Association of multiple copies of c-erbB-2 oncogene with spread of breast cancer. Cancer Res 47:6123-6125, 1987.
19. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989.
20. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257:967-971, 1992.
21. Thompson HJ, McGinley JN, Rothhammer K, Singh M. Rapid induction of mammary intraductal proliferations, ductal carcinoma in situ and carcinomas by the injection of sexually immature female rats with 1-methyl-1-nitrosourea. Carcinogenesis 16:2407-2411, 1995.
22. Thompson HJ, Adlakha A. Dose-responsive induction of mammary gland carcinomas by the intraperitoneal injection of 1-methyl-1-nitrosourea. Cancer Res 51:3411-3415, 1991.
23. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74:5463-5467, 1977.
24. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 215:403-410, 1990.
25. Madsen P, Rasmussen HH, Flint T, et al. Cloning and chromosome mapping of human galectin-7. J Biol Chem 270:5823-5829, 1995.
26. Blesch A, Bosserhoff AK, Apfel R, et al. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 54:5695-5701, 1994.
27. van Groningen JJ, Bloemers HP, Swart GW. Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display. Cancer Res 55:6237-6243, 1995.
28. Dietz UH, Sandell LJ. Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis. J Biol Chem 271:3311-3316, 1996.
29. Singer PA, Trevor K, Oshima RG. Molecular cloning and characterization of the endo B cytokeratin expressed in preimplantation mouse embryos. J Biol Chem 261:538-547, 1986.
30. Romano V, Hatzfeld M, Magin TM, et al. Cytokeratin expression in simple epithelia. I. Identification of mRNA coding for human cytokeratin no. 18 by a cDNA clone. Differentiation 30:244-253, 1986.
31. Kaestner KH, Ntambi JM, Kelly TJ, Lane MD. Differentiation-induced gene expression in 3T3-L1 preadipocytes. A second differentially expressed gene encoding stearoyl-CoA desaturase. J Biol Chem 264:14755-14761, 1989.
32. Barondes SH, Castronovo V, Cooper DN, et al. Galectins: A family of animal beta-galactoside-binding lectins. Letter. Cell 76:597-598, 1994.
33. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 269:20807-20810, 1994.
34. Chiariotti L, Berlingieri MT, Battaglia C, et al. Expression of galectin-1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors. Int J Cancer 64:171-175, 1995.
35. van den Brule FA, Buicu C, Berchuck A, et al. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 27:1185-1191, 1996.
36. Gillenwater A, Xu SC, el-Naggar AK, Clayman GL, Lotan R. Expression of galectins in head and neck squamous cell carcinoma. Head Neck 18:422-432, 1996.
37. Castronovo V, Van Den Brule FA, Jackers P, et al. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 179:43-48, 1996.
38. Schoeppner HL, Raz A, Ho SB, Bresalier RS. Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 75:2818-2826, 1995.
39. Xu XC, el-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 147:815-822, 1995.
40. Huflejt ME, Geradts J, Elliott ML, Leffler H, Liu FT. Galectin-4 is induced in human breast tumors and is localized to sites of cell adhesion in cultured cells. Abstract. Proceedings of the American Association for Cancer Research 38:267-268, 1997.
41. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 93:6737-6742, 1996.
42. Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature 378:736-739, 1995.
43. van den Brule FA, Buicu C, Baldet M, et al. Galectin-1 modulates human melanoma cell adhesion to laminin. Biochem Biophys Res Commun 209:760-767, 1995.
44. Ohannesian DW, Lotan D, Thomas P, et al. Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res 55:2191-2199, 1995.
45. Hebert E, Monsigny M. Galectin-3 mRNA level depends on transformation phenotype in ras-transformed NIH 3T3 cells. Letter. Biol Cell 81:73-76, 1994.
46. Ohannesian DW, Lotan D, Lotan R. Concomitant increases in galectin-1 and its glycoconjugate ligands (carcinoembryonic antigen, lamp-1, and lamp-2) in cultured human colon carcinoma cells by sodium butyrate. Cancer Res 54:5992-6000, 1994.
47. Inohara H, Raz A. Functional evidence that cell surface galectin3 mediates homotypic cell adhesion. Cancer Res 55:3267-3271, 1995.
48. Ochieng J, Warfield P. Galectin-3 binding potentials of mouse tumor EHS and human placental laminins. Biochem Biophys Res Commun 217:402-406, 1995.
49. Bosserhoff AK, Hein R, Wach F, Buettner R. Function of MIA in metastasis of malignant melanoma. Proceedings of the American Association for Cancer Research 38:290, 1997.
50. Oshima RG, Howe WE, Klier FG, Adamson ED, Shevinsky LH. Intermediate filament protein synthesis in preimplantation murine embryos. Dev Biol 99:447-455, 1983.
51. Brulet P, Babinet C, Kemler R, Jacob F. Monoclonal antibodies against trophectoderm-specific markers during mouse blastocyst formation. Proc Natl Acad Sci USA 77:4113-1117, 1980.
52. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell 31:11-24, 1982.
53. Balm AJ, Hageman PC, van Doornewaard MH, Groeneveld EM, Ivanyi D. Cytokeratin 18 expression in squamous cell carcinoma of the head and neck. Eur Arch Otorhinolaryngol 253:227-233, 1996.
54. Thorban S, Roder JD, Nekarda H, Funk A, Siewert JR, Pantel K. lmmunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. J Natl Cancer Inst 88:1222-1227, 1996.
55. Oberneder R, Riesenberg R, Kriegmair M, et al. lmmunocytochemical detection and phenotypic characterization of micrometastatic tumour cells in bone marrow of patients with prostate cancer. Urol Res 22:3-8, 1994.
56. O'Sullivan GC, Collins JK, O'Brien F, et al. Micrometastases in bone marrow of patients undergoing "curative" surgery for gastrointestinal cancer. Gastroenterology 109:1535-1540, 1995.
57. Broers JL, Rot MK, Oostendorp T, et al. lmmunocytochemical detection of human lung cancer heterogeneity using antibodies to epithelial, neuronal, and neuroendocrine antigens. Cancer Res 47:3225-3234, 1987.
58. van Dalen A. Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease. Anticancer Res 16:2345-2349, 1996.
59. Schuurman JJ, Bong SB, Einarsson R. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients. Anticancer Res 16:2169-2172, 1996.
60. Bauman PA, Dalton WS, Anderson JM, Cress AE. Expression of cytokeratin confers multiple drug resistance. Proc Natl Acad Sci USA 91:5311-5314, 1994.
61. Baba H, Fuss B, Watson JB, Zane LT, Macklin WB. Identification of novel mRNAs expressed in oligodendrocytes. Neurochem Res 19:1091-1099, 1994.